Literature DB >> 28540418

Therapy monitoring with PET in cancer patients: achievements, opportunities and challenges ahead for the PET community.

Nicolas Aide1,2,3, Stefano Fanti4,5.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28540418     DOI： 10.1007/s00259-017-3721-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  22 in total

Review 1.  PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.

Authors:  Giampiero Giovacchini; Elisabetta Giovannini; Rossella Leoncini; Mattia Riondato; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-14       Impact factor: 9.236

Review 2.  Using PET for therapy monitoring in oncological clinical trials: challenges ahead.

Authors:  C M Deroose; S Stroobants; Y Liu; L K Shankar; P Bourguet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-27       Impact factor: 9.236

Review 3.  Therapy assessment of bone metastatic disease in the era of 223radium.

Authors:  Elba Etchebehere; Ana Emilia Brito; Alireza Rezaee; Werner Langsteger; Mohsen Beheshti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-31       Impact factor: 9.236

Review 4.  Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments.

Authors:  Katja Pinker; Christopher Riedl; Wolfgang A Weber
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-30       Impact factor: 9.236

5.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Authors:  H Young; R Baum; U Cremerius; K Herholz; O Hoekstra; A A Lammertsma; J Pruim; P Price
Journal:  Eur J Cancer       Date:  1999-12       Impact factor: 9.162

Review 6.  Therapy assessment in multiple myeloma with PET.

Authors:  Cristina Nanni; Elena Zamagni
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-01       Impact factor: 9.236

7.  Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.

Authors:  Jedd D Wolchok; Axel Hoos; Steven O'Day; Jeffrey S Weber; Omid Hamid; Celeste Lebbé; Michele Maio; Michael Binder; Oliver Bohnsack; Geoffrey Nichol; Rachel Humphrey; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

Review 8.  FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas.

Authors:  Sally F Barrington; Regine Kluge
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-14       Impact factor: 9.236

Review 9.  Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician.

Authors:  S Lheureux; C Denoyelle; P S Ohashi; J S De Bono; F M Mottaghy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-10       Impact factor: 9.236

Review 10.  EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies.

Authors:  Nicolas Aide; Charline Lasnon; Patrick Veit-Haibach; Terez Sera; Bernhard Sattler; Ronald Boellaard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-16       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.